Hypertension is altering long-term care for people living with the human immunodeficiency virus across India as medical advancements extend life expectancy.
Antiretroviral treatment has transformed HIV from an acute fatal illness into a manageable chronic condition, but this epidemiological shift brings a growing burden of non-communicable diseases, Cureus reported in a systematic review and meta-analysis.
The coexistence of HIV and high blood pressure creates complex clinical challenges. It elevates cardiovascular risks and complicates treatment strategies through potential drug interactions and adherence hurdles.
India manages a substantial HIV population receiving antiretroviral therapy through national programs while simultaneously confronting a rising public health crisis around high blood pressure. Researchers turned to electronic databases including CENTRAL, PubMed, Scopus, and Web of Science to synthesize available evidence on this overlap.
The systematic review followed PRISMA guidelines and was registered in PROSPERO under registration number CRD420261343183. Out of 315 initial records, reviewers screened 239 titles and abstracts after removing duplicates, ultimately assessing 37 full-text reports and including 12 studies published between 2011 and 2025.
These investigations spanned diverse healthcare settings such as tertiary care hospitals, antiretroviral therapy centers, and private clinics across Delhi, Karnataka, Odisha, Maharashtra, Western India, Kerala, and Puducherry. Participant ages generally ranged from 36 to 56 years, though one study included adults aged 20 to 80.
| Diagnostic Threshold | Included Studies | Operational Criteria |
|---|---|---|
| Standardized High | 6 studies | ≥140/90 mmHg |
| Alternative Cutoff | Various | ≥130/85 mmHg |
| Clinical History | Various | Documented history or physician diagnosis |
Diagnostic criteria varied widely across the evaluated literature. While six studies applied a blood pressure threshold of at least 140/90 mmHg, others relied on documented medical history, a threshold of 130/85 mmHg, multiple criteria, or unspecified definitions.
Methodological quality and risk of bias were assessed independently using the Joanna Briggs Institute critical appraisal checklist. Statistical analyses utilized random-effects models with logit transformation via RStudio to estimate pooled prevalence while accounting for between-study heterogeneity.
Ageing, chronic inflammation, metabolic shifts, and long-term exposure to antiretroviral therapy all influence cardiovascular risk in this demographic. The findings aim to assist clinicians and policymakers in designing integrated care models that simultaneously address communicable and non-communicable conditions.
The review protocol and literature searches outline the current evidence base available to researchers evaluating cardiovascular health in India’s antiretroviral therapy programs.